In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis

In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis

Abstract Despite the efficacy of natalizumab, which targets the integrin VLA-4, in treating multiple sclerosis (MS), approximately 35% patients with MS present evidence of disease activity two years after treatment initiation. Individual heterogeneity of leukocyte response to VLA-4 on natalizumab-me...

Full description

Saved in:
Bibliographic Details
Main Authors: Beatriz Chaves, Juan Carlo Santos e Silva, Helder Nakaya, Nicolas Socquet-Juglard, Florence Bucciarelli, Guilhèn Prunier, Matheus V. Almeida, Claire Lacouture, Saniya Kari, Anne L. Astier, Marco A. Medeiros, João H. M. Silva, Roland Liblau, Vinicius Cotta-de-Almeida, Loïc Dupré
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-60224-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-60224-3

Similar Items